Human metabolism and pharmacological profiling of protonitazepyne and metonitazepyne, two highly potent nitazenes: prediction of main metabolite activity based on µ-opioid receptor docking simulations
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Nitazenes have recently surfaced the illicit opioid market, causing numerous intoxications and fatalities. N -Pyrrolidino derivatives, protonitazepyne and metonitazepyne, have circulated since 2023 and have been involved in overdose intoxications. Their pharmacological properties remain largely unknown. However, pharmacokinetic/dynamic data are crucial for clinicians and toxicologists to manage intoxications and interpret legal cases. Protonitazepyne and metonitazepyne metabolism was assessed using human hepatocyte incubations and blood/urine from an intoxication case; samples were analyzed with liquid chromatography–high-resolution mass spectrometry and software-aided data mining. µ-(MOR), κ-(KOR), and δ-(DOR) opioid receptor activation was assessed using a GTP G i binding assay. MOR docking was simulated with UCSF Chimera and AutoDockSuite. Pharmacological relevance of major metabolites was predicted through in silico MOR docking. Major metabolites were produced through nitroreduction, pyrrolidine N -dealkylation, and oxidation to N -butanoic acid and O -dealkylation. Protonitazepyne and metonitazepyne potencies at MOR were 3.7 and 11.5 nmol L −1 , respectively; efficacies were 154 and 101%. Partial agonism and low potency were observed at KOR/DOR. In silico inhibition constants at MOR for protonitazepyne, 5-amino-protonitazepyne, metonitazepyne, and 5-amino-metonitazepyne were 0.68, 11.45, 1.98, and 2,050 nmol L −1 , respectively. Protonitazepyne and metonitazepyne are MOR-selective full agonists, with potencies about seven and two times higher than fentanyl. These nitazenes present significant health risks through central nervous system/respiratory depression. Their primary metabolites showed lower/marginal in silico MOR affinity, suggesting they might be pharmacologically active, albeit to a much lesser extent than the parent compounds. We propose 5-amino derivatives (blood) and N -butanoic acid derivatives (urine) as biomarkers for detecting consumption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 HRMS/MS spectra of metonitazepyne (A), and major metabolites A1 [5-amino-metonitazepyne (B)], A3 [O-desmethyl metonitazepyne glucuronide (C)], and A13 [N-butanoic acid metonitazene (D)], as well as their suggested fragmentation patterns. HRMS/MS spectra of protonitazepyne (E), and major metabolites B2 [O-desmethyl-protonitazepyne glucuronide (F)], B3 [5-amino-protonitazepyne (G)], and B16 [N-butanoic acid-protonitazene (H)], as well as their suggested fragmentation patterns. A3 = B2; Gluc, glucuronide](https://figures.cochat.ai/paper-figures/a9656d5db428402d92dfa474d6320274/human-metabolism-and-pharmacological-profiling-of-protonitazepyne-and-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Human metabolism work suggests that metonitazene undergoes several biotransformation pathways, including N-deethylation, O-demethylation, hydroxylation, nitro reduction, and glucuronidation, which is important for designing confirmatory toxicology assays [19].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
CHARMM‐GUI: A web‐based graphical user interface for CHARMM
Jo, S., Kim, T., Iyer, V. G., & Im, W. (2008) · Journal of Computational Chemistry · doi:10.1002/jcc.20945 · Cited by 9,284
Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K
Mark, P., & Nilsson, L. (2001) · The Journal of Physical Chemistry A · doi:10.1021/jp003020w · Cited by 4,571
CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data
Huang, J., & MacKerell, A. D. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23354 · Cited by 4,430
OPM database and PPM web server: resources for positioning of proteins in membranes
Lomize, M. A., Pogozheva, I. D., Joo, H., Mosberg, H. I., & Lomize, A. L. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr703 · Cited by 2,151
The calculation of free-energy differences by constrained molecular-dynamics simulations
den Otter, W. K., & Briels, W. J. (1998) · The Journal of Chemical Physics · doi:10.1063/1.477019 · Cited by 183
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Isotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework
Krotulski, A. J., Papsun, D. M., Kacinko, S. L., & Logan, B. K. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa016 · Cited by 146
Research works printed but not linked: 1
- Berardinelli D, Taoussi O, Carlier J et al (2024) In vitro, in vivo metabolism and quantification of the novel synthetic opioid N-piperidinyl etonitazene (etonitazepipne). Clin Chem Lab Med 62:1580–1590. https://doi.org/10.1515/CCLM-2023-1360/DOWNLOADASSET/SUPPL/J_CCLM-2023-1360_SUPPL_001.DOCX · doi:10.1515/cclm-2023-1360/downloadasset/suppl/j_cclm-2023-1360_suppl_001.docx
Cited by
Maxwell, M. K., Anwar, A. I., Hasoon, J., & Kaye, A. D. (2026) · Current Pain and Headache Reports · doi:10.1007/s11916-026-01525-0
“Human metabolism work suggests that metonitazene undergoes several biotransformation pathways, including N-deethylation, O-demethylation, hydroxylation, nitro reduction, and glucuronidation, which is important for designing confirmatory toxicology assays [ 19].”
Mechanistic insights into nitazenes at the μ-opioid receptor
Xia, L., Jin, M., & Lu, L. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.04.009
Zemp, S., Alluisetti, G., Weinmann, W., Schrag, B., Sporkert, F., Leclerc, M., & Grafinger, K. E. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70095
“However, recent publications that investigated the metabolism of structurally related nitazenes reported analog metabolites to M4 [27, 28].”
Endogenous opiates and behavior: 2025
Bodnar, R. J. (2026) · Peptides · doi:10.1016/j.peptides.2026.171512
Zschiesche, A., Nadler, J., Pulver, B., Scheu, M., Auwärter, V., & Hermanns‐Clausen, M. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1951240
Self-citation
Metadata
- Authors
- Berardinelli, D., Taoussi, O., Ovat, D. Y., Pichini, S., Pulver, B., Auwärter, V., Busardò, F. P., Basile, G., Laudadio, E., & Carlier, J.
- Affiliations
- Marche Polytechnic University (IT)
- Ege University (TR)
- Istituto Superiore di Sanità (IT)
- University of Freiburg (DE)
- Corresponding author
- Busardò, Francesco Paolo
- ORCID
- Venue
- Archives of Toxicology
- Published
- 2025-10-31
- Volume
- 100
- Issue
- 2
- Pages
- 543-556
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- PMC
- PMC12886327
- OpenAlex
- W4415720996
- Cited by
- 5
- References
- 30
- Citations by year
- 2026: 5
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Archives of Toxicology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion, cc-by)
- Funders
- Università Politecnica delle Marche
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- nitazenes, opioid metabolites, mu-opioid receptor, kappa opioid receptor, delta opioid receptor, nitro group reduction, pharmacokinetics, hepatocyte incubation, GTPgammaS binding, receptor docking, biomarkers, respiratory depression
- MeSH terms
- Analgesics, Opioid, Humans, Pyrrolidines, Receptors, Opioid, mu, Hepatocytes, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human metabolism and pharmacological profiling of protonitazepyne and metonitazepyne, two highly potent nitazenes: prediction of main metabolite activity based on µ-opioid receptor docking simulations. https://app.cochat.ai/papers/10.1007/s00204-025-04163-4
- The paper
- Berardinelli, D., Taoussi, O., Ovat, D. Y., Pichini, S., Pulver, B., Auwärter, V., Busardò, F. P., Basile, G., Laudadio, E., & Carlier, J. (2026). Human metabolism and pharmacological profiling of protonitazepyne and metonitazepyne, two highly potent nitazenes: prediction of main metabolite activity based on µ-opioid receptor docking simulations. Archives of Toxicology. https://doi.org/10.1007/s00204-025-04163-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.